Zydus Lifesciences Erythromycin Tablets bags USFDA nod
The drugs will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad.
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) for Erythromycin Tablets USP, 250 mg and 500 mg (USRLD: Erythromycin Tablets).
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, legionnaire's disease, pertussis and syphilis.
The drugs will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Read also: Zydus Lifesciences secures USFDA okay for Lenalidomide Capsules to treat cancer
Erythromycin Tablets USP, 250 mg and 500 mg had annual sales of USD 25.1 mn in the United States (IQVIA MAT Dec. 2022).
Medical Dialogues team had earlier reported that the company had received final approval from the USFDA to market Micafungin for Injection, 50 mg/vial, and 100 mg/vial, single-dose vials (USRLD: Mycamine). Micafungin for Injection is indicated to treat variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem cell transplant.
Read also: Zydus Lifesciences bags USFDA okay for Fungal infection treatment
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
The group now has 350 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: USFDA approves Zydus Lifesciences Infantile spasm drug Vigabatrin
